EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

AAV delivery of full-length SYNGAP1 rescues epileptic and behavioral phenotypes in a mouse model of SYNGAP1-related disorders

Meagan A Quinlan, Rong Guo, Andrew G Clark, Emily M Luber, Robert J Christian, Refugio A Martinez, Erin L Groce, Jiatai Liu, Yemeserach M Bishaw, Ravi Bhowmik, Elizabeth Liang, Melissa Reding und 11 weitere

Molecular Therapy · 2025-12 · 33 (12) · 6398-6414

DOI: 10.1016/j.ymthe.2025.09.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025-12. Verfasst von Meagan A Quinlan und 22 weiteren Autor:innen. Beteiligte Einrichtung: Allen Institute for Brain Science, Seattle, WA 98109, USA. Hauptthemen laut MEDLINE: Dependovirus, ras GTPase-Activating Proteins, Genetic Vectors, Genetic Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Paul G Allen Family Foundation, BioMarin Pharmaceutical Inc, Allen Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SYNGAP1-related disorders (SRDs) are rare neurodevelopmental conditions characterized by severe neurological symptoms, including epilepsy, motor impairment, and cognitive dysfunction. Current treatment options are limited, with patients relying on a cocktail of medications to manage the diverse symptoms but that do not address the underlying pathology. SRDs are primarily caused by haploinsufficiency of the SYNGAP1 gene, which encodes the synaptic scaffolding and signaling protein, SynGAP. We developed a gene supplementation strategy to deliver broad neuronal expression of human SYNGAP1 via an adeno-associated virus (AAV). Driven by the pan-neuronal SYNAPSIN I promoter, SYNGAP1 delivery alleviated several disease phenotypes in a Syngap1 heterozygous mouse model, including epileptiform activity, hyperactivity, and risk-taking behaviors. Notably, AAV-SYNGAP1 administration in juvenile mice, which corresponds to the typical age of diagnosis in humans, rescued behavioral deficits, highlighting its clinical relevance. Our findings provide the first evidence that AAV-mediated gene therapy can restore SYNGAP1 function and reverse key phenotypes, supporting its potential as a transformative therapeutic for SRD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dependovirusras GTPase-Activating ProteinsGenetic VectorsGenetic TherapyEpilepsyAnimalsMiceDisease Models, AnimalHumansPhenotypeBehavior, AnimalGene Transfer Techniques

Stichwörter der Autor:innen

AAVDEESYNGAP1SynGAPbehaviorepilepsygene therapyintellectual disabilityinterictal spikesseizures

Substanzen

ras GTPase-Activating ProteinsSYNGAP1 protein, human

Autor:innen und Institutionen

  • Allen Institute for Brain Science, Seattle, WA 98109, USA.
  • BioMarin Pharmaceutical, San Rafael, CA 94902, USA.
  • Allen Institute for Brain Science, Seattle, WA 98109, USA; Department of Neurobiology and Biophysics, University of Washington, Seattle, WA 98195, USA.
  • Allen Institute for Brain Science, Seattle, WA 98109, USA; Department of Neurological Surgery, University of Washington, Seattle, WA 98195, USA.
  • Allen Institute for Brain Science, Seattle, WA 98109, USA. Electronic address: boazl@alleninstitute.org.

Förderung

  • Paul G Allen Family Foundation
  • BioMarin Pharmaceutical Inc
  • Allen Institute

Zitieren

APA

Quinlan, M. A., Guo, R., Clark, A. G., Luber, E. M., Christian, R. J., Martinez, R. A., Groce, E. L., Liu, J., Bishaw, Y. M., Bhowmik, R., Liang, E., Reding, M., Ronellenfitch, K., Wright, V., Gudsnuk, K. M., Leedy, J. M., Mich, J. K., Gore, B. B., Daigle, T. L., …, & Levi, B. P. (2025). AAV delivery of full-length SYNGAP1 rescues epileptic and behavioral phenotypes in a mouse model of SYNGAP1-related disorders. Molecular Therapy, 33(12), 6398-6414. https://doi.org/10.1016/j.ymthe.2025.09.040

Vancouver

Quinlan MA, Guo R, Clark AG, Luber EM, Christian RJ, Martinez RA, et al. AAV delivery of full-length SYNGAP1 rescues epileptic and behavioral phenotypes in a mouse model of SYNGAP1-related disorders. Molecular Therapy. 2025;33(12):6398-6414. doi:10.1016/j.ymthe.2025.09.040

BibTeX
@article{Quinlan2025,
  author = {Quinlan, Meagan A and Guo, Rong and Clark, Andrew G and Luber, Emily M and Christian, Robert J and Martinez, Refugio A and Groce, Erin L and Liu, Jiatai and Bishaw, Yemeserach M and Bhowmik, Ravi and Liang, Elizabeth and Reding, Melissa and Ronellenfitch, Kara and Wright, Vonn and Gudsnuk, Kathryn M and Leedy, Jennifer M and Mich, John K and Gore, Bryan B and Daigle, Tanya L and Lopez, Manuel E and Lein, Ed S and Ichida, Justin K and Levi, Boaz P},
  title = {AAV delivery of full-length SYNGAP1 rescues epileptic and behavioral phenotypes in a mouse model of SYNGAP1-related disorders},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {12},
  pages = {6398--6414},
  doi = {10.1016/j.ymthe.2025.09.040}
}
Kostenlos starten →